Literature DB >> 16158071

Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.

Cristiana Griffante1, Andrew Green, Ornella Curcuruto, Carl P Haslam, Bryony A Dickinson, Roberto Arban.   

Abstract

1 A possible role of arginine vasopressin (AVP) V(1b) receptor subtype in stress-related disorders has been recently highlighted by the discovery of the agonist [1-deamino-4-cyclohexylalanine] AVP (d[Cha(4)]AVP) and the antagonist SSR149415. Both compounds have been proposed to target specifically V(1b) receptors, since the reported affinities for the related V(1a), V(2) and oxytocin receptors are in the micromolar or submicromolar range. In the present study, we further investigated the binding affinities of d[Cha(4)]AVP and SSR149415 at recombinant human vasopressin V(1b) (hV(1b)) and oxytocin (hOT) receptors expressed in Chinese hamster ovary (CHO) cells and functional properties of both compounds at hV(1b), hV(1a), hV(2) and hOT receptors. 2 d[Cha(4)]AVP bound to hV(1b) receptors and hOT receptors with pK(i) values of 9.68+/-0.06 and 7.68+/-0.09, respectively. SSR149415 showed pK(i) values of 9.34+/-0.06 at hV(1b) and 8.82+/-0.16 at hOT receptors. 3 d[Cha(4)]AVP stimulated [Ca(2+)](i) increase in hV(1b)-CHO cells with a pEC(50) value of 10.05+/-0.15. It showed pEC(50) values of 6.53+/-0.17 and 5.92+/-0.02 at hV(1a) and hV(2) receptors, respectively, and behaved as a weak antagonist at hOT receptors (pK(B)=6.31+/-0.12). SSR149415 inhibited the agonist-induced [Ca(2+)](i) increase with pK(B) values of 9.19+/-0.07 in hV(1b)-CHO and 8.72+/-0.15 in hOT-CHO cells. A functional pK(i) value of 7.23+/-0.10 was found for SSR1494151 at hV(1a) receptors, whereas it did not inhibit 20 nM AVP response at hV(2) receptors up to 3 microM. 4 Data obtained confirmed the high potency and selectivity of d[Cha(4)]AVP at hV(1b) receptors, but revealed that SSR149415, in addition to the high potency at hV(1b) receptors, displays a significant antagonism at hOT receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158071      PMCID: PMC1751202          DOI: 10.1038/sj.bjp.0706383

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus.

Authors:  I D Neumann; A Wigger; L Torner; F Holsboer; R Landgraf
Journal:  J Neuroendocrinol       Date:  2000-03       Impact factor: 3.627

2.  Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

Authors:  P D Williams; M G Bock; B E Evans; R M Freidinger; S N Gallicchio; M T Guidotti; M A Jacobson; M S Kuo; M R Levy; E V Lis; S R Michelson; J M Pawluczyk; D S Perlow; D J Pettibone; A G Quigley; D R Reiss; C Salvatore; K J Stauffer; C J Woyden
Journal:  Bioorg Med Chem Lett       Date:  1999-05-03       Impact factor: 2.823

3.  Analysis of Apparent Noncompetitive Responses to Competitive H(1)-Histamine Receptor Antagonists in Fluorescent Imaging Plate Reader-Based Calcium Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

4.  AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters.

Authors:  Robert J Blanchard; Guy Griebel; Catherine Farrokhi; Chris Markham; Mu Yang; D Caroline Blanchard
Journal:  Pharmacol Biochem Behav       Date:  2004-12-15       Impact factor: 3.533

5.  Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.

Authors:  S B Paranjape; M Thibonnier
Journal:  Expert Opin Investig Drugs       Date:  2001-05       Impact factor: 6.206

6.  Molecular pharmacology of human vasopressin receptors.

Authors:  M Thibonnier; D M Conarty; J A Preston; P L Wilkins; L N Berti-Mattera; R Mattera
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

Review 7.  Vasopressin as a target for antidepressant development: an assessment of the available evidence.

Authors:  Lucinda V Scott; Timothy G Dinan
Journal:  J Affect Disord       Date:  2002-11       Impact factor: 4.839

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.

Authors:  Y Yamamura; H Ogawa; T Chihara; K Kondo; T Onogawa; S Nakamura; T Mori; M Tominaga; Y Yabuuchi
Journal:  Science       Date:  1991-04-26       Impact factor: 47.728

Review 10.  Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age.

Authors:  F A Antoni
Journal:  Front Neuroendocrinol       Date:  1993-04       Impact factor: 8.606

View more
  15 in total

1.  Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.

Authors:  Eléonore Beurel; Charles B Nemeroff
Journal:  Curr Top Behav Neurosci       Date:  2014

2.  Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.

Authors:  M Iijima; T Yoshimizu; T Shimazaki; K Tokugawa; K Fukumoto; S Kurosu; T Kuwada; Y Sekiguchi; S Chaki
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats.

Authors:  Scott Edwards; Miguel Guerrero; Ola M Ghoneim; Edward Roberts; George F Koob
Journal:  Addict Biol       Date:  2011-02-11       Impact factor: 4.280

5.  The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors.

Authors:  Stephen J Lolait; Lesley Q Stewart; David S Jessop; W Scott Young; Anne-Marie O'Carroll
Journal:  Endocrinology       Date:  2006-11-22       Impact factor: 4.736

Review 6.  The vasopressin 1b receptor and the neural regulation of social behavior.

Authors:  Erica L Stevenson; Heather K Caldwell
Journal:  Horm Behav       Date:  2011-12-07       Impact factor: 3.587

7.  Attenuated stress response to acute restraint and forced swimming stress in arginine vasopressin 1b receptor subtype (Avpr1b) receptor knockout mice and wild-type mice treated with a novel Avpr1b receptor antagonist.

Authors:  J A Roper; M Craighead; A-M O'Carroll; S J Lolait
Journal:  J Neuroendocrinol       Date:  2010-11       Impact factor: 3.627

Review 8.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

9.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Authors:  Rafik Marir; Anne Virsolvy; Kazimierz Wisniewski; Julie Mion; Dominique Haddou; Evelyne Galibert; Zahia Meraihi; Michel G Desarménien; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 10.  Depression and antidepressants: molecular and cellular aspects.

Authors:  Cristina Lanni; Stefano Govoni; Adele Lucchelli; Cinzia Boselli
Journal:  Cell Mol Life Sci       Date:  2009-06-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.